143 related articles for article (PubMed ID: 30686358)
1. [Not Available].
Chabannon C; Larghero J
Bull Cancer; 2018 Dec; 105 Suppl 2():S198-S204. PubMed ID: 30686358
[TBL] [Abstract][Full Text] [Related]
2. [Not Available].
Rahal I; Cabannes-Hamy A; Boissel N
Bull Cancer; 2018 Dec; 105 Suppl 2():S158-S167. PubMed ID: 30686354
[TBL] [Abstract][Full Text] [Related]
3. [Not Available].
Dourthe MÉ; Yakouben K; Chaillou D; Lesprit E; Dalle JH; Baruchel A
Bull Cancer; 2018 Dec; 105 Suppl 2():S147-S157. PubMed ID: 30686353
[TBL] [Abstract][Full Text] [Related]
4. [Not Available].
Gauthier J
Bull Cancer; 2018 Dec; 105 Suppl 2():S214-S217. PubMed ID: 30686360
[TBL] [Abstract][Full Text] [Related]
5. [Not Available].
Le Bourgeois A
Bull Cancer; 2018 Dec; 105 Suppl 2():S188-S197. PubMed ID: 30686357
[TBL] [Abstract][Full Text] [Related]
6. [Not Available].
Salles G; Sesques P; Ferrant E; Safar V; Ghesquieres H; Bachy E
Bull Cancer; 2018 Dec; 105 Suppl 2():S168-S177. PubMed ID: 30686355
[TBL] [Abstract][Full Text] [Related]
7. [Not Available].
Pinturaud M; Vasseur M; Odou P
Bull Cancer; 2018 Dec; 105 Suppl 2():S205-S213. PubMed ID: 30686359
[TBL] [Abstract][Full Text] [Related]
8. [Not Available].
Rubio MT; Galaine J; Borg C; Daguindau É
Bull Cancer; 2018 Dec; 105 Suppl 2():S135-S146. PubMed ID: 30686352
[TBL] [Abstract][Full Text] [Related]
9. [Not Available].
Alcazer V; Delenda C; Poirot L; Depil S
Bull Cancer; 2018 Dec; 105 Suppl 2():S178-S187. PubMed ID: 30686356
[TBL] [Abstract][Full Text] [Related]
10. Considerations pertaining to cell collection and administration of industry-manufactured autologous CAR-T cells, in relation to French healthcare organization and regulations.
Chabannon C; Larghero J
Curr Res Transl Med; 2018 May; 66(2):59-61. PubMed ID: 29625832
[TBL] [Abstract][Full Text] [Related]
11. [CAR-T CELLS: How does the EBMT registry monitor European activities, identify hurdles and prepare for changes in regulations].
Chabannon C; Lemaitre J; Peffault de Latour R; Neven B; Bay JO; Robin M; Kuball J; Terwel S; Mohty M; Yakoub-Agha I
Bull Cancer; 2021 Oct; 108(10S):S155-S161. PubMed ID: 34920798
[TBL] [Abstract][Full Text] [Related]
12. [Quality assessment of CAR T-cell activity: Recommendations of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
Duléry R; Lacassagne MN; Giraud C; Ader V; Beaumont JL; Carnoy S; Carpentier A; Fegueux N; Gibault-Joffe C; Guerout-Verite MA; Huynh TNP; Lewalle P; Perrin A; Plaza-Milhe S; Bonnin A; Yakoub-Agha I; Contentin N
Bull Cancer; 2020 Dec; 107(12S):S193-S201. PubMed ID: 33187683
[TBL] [Abstract][Full Text] [Related]
13. [CAR-T cells gene therapy medicines: Regulatory status and pharmaceutical circuits in Europe and France].
de Jorna R; Madelaine I; Larghero J; Mebarki M
Bull Cancer; 2021 Oct; 108(10S):S162-S167. PubMed ID: 34920799
[TBL] [Abstract][Full Text] [Related]
14. [Prerequisite for hematopoietic cellular therapy programs to set up chimeric antigen receptor T-cell therapy (CAR T-cells): Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
Yakoub-Agha I; Ferrand C; Chalandon Y; Ballot C; Castilla Llorente C; Deschamps M; Gauthier J; Labalette M; Larghero J; Maheux C; Moreau AS; Varlet P; Pétillon MO; Pinturaud M; Rubio MT; Chabannon C
Bull Cancer; 2017 Dec; 104(12S):S43-S58. PubMed ID: 29174320
[TBL] [Abstract][Full Text] [Related]
15. Evolution of CAR T-cell immunotherapy in terms of patenting activity.
Jürgens B; Clarke NS
Nat Biotechnol; 2019 Apr; 37(4):370-375. PubMed ID: 30940940
[No Abstract] [Full Text] [Related]
16. Chimeric Antigen Receptor T-Cell Therapy for the Community Oncologist.
Maus MV; Levine BL
Oncologist; 2016 May; 21(5):608-17. PubMed ID: 27009942
[TBL] [Abstract][Full Text] [Related]
17. Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis.
Zhang T; Cao L; Xie J; Shi N; Zhang Z; Luo Z; Yue D; Zhang Z; Wang L; Han W; Xu Z; Chen H; Zhang Y
Oncotarget; 2015 Oct; 6(32):33961-71. PubMed ID: 26376680
[TBL] [Abstract][Full Text] [Related]
18. Optimization of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma.
Brown CE; Aguilar B; Starr R; Yang X; Chang WC; Weng L; Chang B; Sarkissian A; Brito A; Sanchez JF; Ostberg JR; D'Apuzzo M; Badie B; Barish ME; Forman SJ
Mol Ther; 2018 Jan; 26(1):31-44. PubMed ID: 29103912
[TBL] [Abstract][Full Text] [Related]
19. Current status and regulatory perspective of chimeric antigen receptor-modified T cell therapeutics.
Kim MG; Kim D; Suh SK; Park Z; Choi MJ; Oh YK
Arch Pharm Res; 2016 Apr; 39(4):437-452. PubMed ID: 26895243
[TBL] [Abstract][Full Text] [Related]
20. Integration of a CD19 CAR into the TCR Alpha Chain Locus Streamlines Production of Allogeneic Gene-Edited CAR T Cells.
MacLeod DT; Antony J; Martin AJ; Moser RJ; Hekele A; Wetzel KJ; Brown AE; Triggiano MA; Hux JA; Pham CD; Bartsevich VV; Turner CA; Lape J; Kirkland S; Beard CW; Smith J; Hirsch ML; Nicholson MG; Jantz D; McCreedy B
Mol Ther; 2017 Apr; 25(4):949-961. PubMed ID: 28237835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
